The difference between secukinumab and secukinumab

Secukinumab is another name for Secukinumab, which belongs to the same drug and is a human interleukin-17A antagonist. It is indicated for patients 6 years and older with moderate to severe plaque psoriasis and is a candidate for systemic treatment or phototherapy. Also indicated for active psoriatic arthritis (PsA) in patients 2 years of age and older, adults with active ankylosing spondylitis (AS), and adults with active nonradiographic axial spondyloarthritis (nr-axSpA), including objective signs of inflammation. Secukinumab also treats active enthesitis-associated arthritis (ERA) in patients 4 years of age and older.